A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update
Impact in
Classified as
- Journal
- European Journal of Cancer
In The Last Decade
doi.org/10.1016/j.ejca.2012.12.010 →Countries where authors are citing A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update
This map shows the geographic impact of A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update more than expected).
Fields of papers citing A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update
This network shows the impact of A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update.
About A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update
This paper, published in 2013, received 363 indexed citations . Written by Cora N. Sternberg, Robert E. Hawkins, John Wagstaff, Pamela Salman, Jozef Mardiak, Carlos H. Barrios, Juan José Zarbá, Oleg Gladkov, Eunsik Lee and Cezary Szczylik covering the research area of Pulmonary and Respiratory Medicine. It is primarily cited by scholars working on Pulmonary and Respiratory Medicine (280 citations), Molecular Biology (146 citations), Cancer Research (105 citations), Oncology (67 citations) and Economics and Econometrics (20 citations). Published in European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/10.1016/j.ejca.2012.12.010.